Search results
Results from the WOW.Com Content Network
Familial partial lipodystrophy, also known as Köbberling–Dunnigan syndrome, [2] is a rare genetic metabolic condition characterized by the loss of subcutaneous fat. [ 3 ] : 495 FPL also refers to a rare metabolic condition in which there is a loss of subcutaneous fat in the arms, legs and lower torso.
Familial Partial Lipodystrophy, Dunnigan Type Autosomal dominant is the manner of inheritance of this condition Dunnigan-type familial partial lipodystrophy , also known as FPLD Type II and abbreviated as ( FPLD2 ), is a rare monogenic form of insulin resistance characterized by loss of subcutaneous fat from the extremities , trunk , and ...
The medicine is used in: adults and children above the age of two years with generalised lipodystrophy (Berardinelli-Seip syndrome and Lawrence syndrome) and in adults and children above the age of 12 years with partial lipodystrophy (including Barraquer-Simons syndrome), when standard treatments have failed. [15]
Familial cold autoinflammatory syndrome; Familial Mediterranean fever; Familial partial lipodystrophy; Familial Adenomatous Polyposis; Fanconi syndrome; Favre–Racouchot syndrome; Febrile infection-related epilepsy syndrome; Febrile neutrophilic dermatosis; Fechtner syndrome; Feingold syndrome; Feline hyperesthesia syndrome; Felty's syndrome ...
Barraquer–Simons syndrome (acquired partial lipodystrophy, cephalothoracic lipodystrophy, progressive lipodystrophy) Benign symmetric lipomatosis (benign symmetric lipomatosis of Launois–Bensaude, Madelung's disease) Centrifugal abdominal lipodystrophy (centrifugal lipodystrophy, lipodystrophia centrifugalis abdominalis infantalis)
Lipoprotein lipase deficiency is a genetic disorder in which a person has a defective gene for lipoprotein lipase, which leads to very high triglycerides, which in turn causes stomach pain and deposits of fat under the skin, and which can lead to problems with the pancreas and liver, which in turn can lead to diabetes.
Standard guidelines for the management of renal disease should be followed. The course of membranoproliferative glomerulonephritis in acquired partial lipodystrophy has not been significantly altered by treatment with corticosteroids or cytotoxic medications. Recurrent bacterial infections, if severe, might be managed with prophylactic antibiotics.
Lipedema has been described in familial clusters, suggesting a genetic component. [9] It often appears around times of hormonal change such as puberty, pregnancy, and menopause, suggesting a potential hormonal component. [10] Having obesity doesn’t cause lipedema, but more than half of people with this condition have a BMI higher than 35. [11]